部分线粒体参与PT-112的抗增殖和免疫刺激作用
Ruth Soler-Agesta1,2, Manuel Beltrán-Visiedo1,3, Ai Sato1,3
1Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
Oncoimmunology
|May 19, 2025
概括
新型癌症药物PT-112通过触发免疫细胞死亡 (ICD) 来抑制瘤细胞的生长. 它的有效性部分与线粒体外膜通透性 (MOMP) 相关,但即使在MOMP缺陷的细胞中,它仍然活跃.
科学领域:
- 在瘤学瘤学.
- 癌症免疫学 癌症免疫学
- 分子生物学分子生物学
背景情况:
- PT-112是一种新型小分子,已证明对固体瘤的临床活性.
- 它通过抑制核糖体生物发生和诱导免疫刺激信号来起作用,将其归类为免疫细胞死亡 (ICD) 诱导剂.
- PT-112与免疫检查点抑制剂协同作用,在单一治疗中显示持久反应.
研究的目的:
- 研究线粒体外膜透 (MOMP) 在调解PT-112活性中的作用.
- 确定影响MOMP的遗传变化是否影响PT-112的细胞毒性和免疫性.
主要方法:
- 使用了小鼠乳腺癌TS/A细胞,具有不同的MOMP能力.
- 评估了PT-112对细胞增殖,细胞毒性,卡莱蒂库林 (CALR) 暴露,HMGB1释放,eIF2α酸化,I型IFN分泌和MHC I类/PD-L1表面表达的影响.
主要成果:
- PT-112表现出强大的抗增殖和细胞毒性作用,诱导TS/A细胞中的ICD标记物 (CALR暴露,HMGB1释放).
- MOMP能力影响了急性细胞毒性和HMGB1释放.
- PT-112保持了抗增殖活性和免疫刺激作用 (I型IFN,CALR,MHC I类,PD-L1暴露),无论MOMP状态如何.
结论:
- 线粒体外膜通透性 (MOMP) 部分导致PT-112的作用机制.
- PT-112具有广泛的活性,即使在MOMP有缺陷的瘤类型中也是有效的.
相关概念视频
Electron Transport Chain: Complex I and II
10.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
10.0K
Mitochondria
9.3K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
9.3K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


